What is the current landscape of antibodies targeting membrane proteins? As of June 2022, 162 antibodies had been approved for a wide array of diseases in the world, including cancers, immune-related diseases, infectious diseases, and hematological diseases1. Over half target membrane proteins, primarily proteins with large extracellular domains and simple transmembrane domains such as tyrosine…

By Lynn Miranda, Sales Manager for All Packaging Machinery Corp, Ronkonkoma, NY. The customer’s level of confidence and trust is everything. This especially occurs when supplying pouch-sealing machinery for the medical and pharmaceutical industry. I have been taught to evaluate the application and discuss the features of the validation medical pouch-sealing machinery side-by-side to the…

Raumedic is a trusted partner in the international medical technology and pharmaceutical industry. The medical division of the global corporation REHAU, a family-owned company, has over 70 years of tried and trusted experience in extrusion, injection molding and assembly. With a focus on developing and manufacturing components for a diverse range of diagnostic and therapeutic…

Losing university access doesn’t mean losing access to articles anymore By DeepDyve Digital Library Team Many researchers are surprised to find that leaving university also means leaving behind something they didn’t expect—easy access to peer-reviewed literature. Especially for those who have gone to work at startups or other smaller organizations, finding a way to do…

By Sino Biological Therapeutic monoclonal antibodies have emerged as the fastest-growing class of therapeutics since the mid-1980s from the increasing number of pharmaceutical companies seeking more drug modalities to extend their pipelines. Additionally, biosimilars now have more opportunities to enter the market as patents of some blockbuster monoclonal antibodies begin to expire. Given this context,…

As we have seen with certain vaccines over the last 18 months, cryogenic transport and storage is becoming a significant issue for biopharmaceutical manufacturers as more products and components must be stored at very low temperatures to be kept functional. The repercussions of these new requirements are being felt throughout the biopharmaceutical production industry as…

Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug therapies By Tim McLeroy, Executive Director of Marketing & Patient Services The global market for medical devices is approximately $436 billion, bolstered by an aging population, according to data from hfMEDIC, the University of Utah-led…

The March/April 2019 issue takes a look at: Pharma Execs Face the Feds Four Air Cargo Trends Shaping the Transport of Pharmaceuticals Scalable Viral Vector Manufacturing Advances in Vial Processing in Pharmaceutical Primary Packaging to Reduce Risk of Vial Damage and Particle Contamination Converting to a “Batch-less” World: Quality Implications of Continuous Manufacturing New Friends for…

The January/February 2019 issue takes a look at: The Rapid Rise of Modular Construction Manufacturing Amorphous SDDs for Compounds Prone to Crystallization Pharma Facility Upgrades Understanding the FDA’s Priority Review Voucher System A Planner’s Guide to Filtered Fume Hoods What You Need to Know about Cleanroom Attire The Critical Link Between Particle Monitoring Systems and Business Continuity…